(ID：mic-sh366) 以下文章来源于深蓝观 ，作者深蓝观团队 深蓝观 . 医药领域深度观察，深一点，远一点...... 悲剧发生。 作者/王晨 石慧玲 来源/深蓝观 然而，诡异的是，这家僵尸公司的账户里，却依然时不时有钱打进来。 一 家 其 实 已 经 " 死 亡 " 多 年 的 生 物 科 技 公 司 ， 在 最 后 一 刻 ， 突 然 向 市 场 抛 出 了 最 后 一 次"遗产分配"。 2 0 2 4年2月1 3日，FDA批准了On i v y d e（MM- 3 9 8）（伊立替康脂质体注射液）为基础 的四药联合方案，用于转移性胰腺癌的一线治疗。 这是一项标准意义上的"临床进展新闻"。但这项批准，却在资本市场上触发了一场迟到 多年的"终局回声"。 这 一 天 ， 法 国 药 企 益 普 生 （ I p s e n ） 按 协 议 向 Me rrima c k P h a rma c e u t i c a ls 支 付 了 2 . 2 5亿美元的里程碑付款。而这，也成为了 Me rrima c k 这家公司此生最后一笔收入。 紧接着，更戏剧性的一幕发生了。 Me rrima c k 在 公 告 ...

"'深圳市AI驱动医药研发公共服务平台组建项目'正是在这一背景下应运而生的。"深圳理工大学药学院院 长陈有海表示，该平台旨在构建覆盖药物研发全链条的公共技术服务平台，为高校、科研院所及医药企业 等提供AI辅助药物发现、优化与药效评估等一站式服务，助力降低研发成本与风险、缩短研发周期，提升 研发效率并加速成果转化。 深圳理工大学秉持"科教融汇、产教融合"理念，积极构建"基础研究—技术攻关—成果转化"体系，为平台 建设提供了坚实的智力支持和创新动力。技术层面，深圳理工大学依托学科交叉优势，组建跨领域研究团 队，为平台提供源头创新动力；协同层面，实现高校与企业深度联动，整合高校科研优势与企业产业资 源，形成了产学研融合的创新样本；人才方面，学校汇聚了一批国内外顶尖科研力量，在人工智能、生物 医药等领域取得了一系列重要成果。 复星医药作为国内领先的医药产业集团，拥有丰富的产业资源和强大的市场拓展能力。其在药物研发、生 产、销售等环节积累了丰富的经验，能够为平台提供实践应用场景和产业反馈，促进科研成果的快速转化 和商业化。 南都讯 记者伍曼娜近日，深圳市发展和改革委员会正式批复2025年第一批战略性新兴产业扶持计划拟资 ...

累计服务超过1000家药企， 并通过40000余个项目的实战交付。 "我们不再是交付单一功能的模块，而是交付一个能够协同完成临床试验全流程的'AI智能体集群'。"李星对36氪表示："我们的核心壁垒在于用'认知原子 论'去重构研发流程，系统将复杂的临床试验拆解为上万个微小的原子化任务，每个任务由专精的Agent负责，它们通过类似脑神经的突触网络连接，实现了 远超通用大模型的专业度。" 图源：深度智耀 这种技术架构的演进，在一定程度上推动了商业模式的变革。在行业普遍采用"按人头/工时付费"的传统模式下，深度智耀开始探索基于里程碑的价值付费 （Outcome-based Model）。 文 ｜ 胡香赟 编辑 ｜ 海若镜 封面来源 ｜ IC Photo 36氪获悉，AI制药全球领军企业深度智耀近期获近5000万美元D轮融资。本轮融资由鼎晖百孚领投，老股东 新鼎资本、 红杉中国持续加注，指数资本担任 独家财务顾问。募集资金将主要用于"多智能体协作网络"的技术研发迭代及全球交付网络的建设。 深度智耀成立于2017年。相较于早期在单一技术点上的探索，过去三年，深度智耀完成了从"单点AI技术验证"向"AI原生临床研究平台（A ...

Core Viewpoint - The AI pharmaceutical technology developed by the company has positively impacted its business and performance, with substantial data supporting this claim [2] Group 1: Technology Impact - As of August 2025, the company's CADD/AIDD technology platform has provided technical support for 95 new drug projects, with 7 projects entering clinical trial stages [2] - The platform has served a total of 45 clients across various therapeutic areas, indicating its broad applicability and acceptance in the industry [2] Group 2: Strategic Importance - The technology platform represents a significant upgrade from traditional drug development to a more intelligent and systematic approach, becoming a core support for the company's new drug discovery strategic transformation [2]

其余备案企业还包括：青岛国恩科技拟发行不超过5405万股；深圳创智芯联科技拟发行不超过4397.72 万股；AI制药领域企业英矽智能（InSilico Medicine Cayman TopCo）拟发行不超过1.0889亿股；深圳市 沃尔核材拟发行不超过1.6099亿股。 此次多家热门赛道企业密集获得港股IPO备案，既体现了香港市场对优质科技企业的强大吸引力，也反 映出相关领域企业加速拓展国际融资渠道、提升全球品牌影响力的迫切需求。港股的国际化平台优势， 将为这些企业引入全球资本，助力其在技术研发与市场拓展上实现更大突破。 亿配芯城（ICgoodFind）：企业扎堆冲刺港股彰显行业活力，我们将持续联动产业链优质资源，助力 相关企业实现供应链高效配套。 12月9日晚间，中国证监会网站披露重磅消息，9家企业境外发行上市备案通知书正式落地，均计划发行 境外上市普通股并登陆香港联合交易所主板，涵盖半导体、机器人、自动化等多个高景气赛道，掀起一 波港股上市热潮。 此次备案名单星光熠熠，半导体领域巨头齐聚：全球排名前列的中国半导体设计公司豪威集团，拟发行 不超过7367.02万股；互连类芯片领军企业澜起科技，计划发行不超 ...

Core Insights - The biopharmaceutical industry in Hangzhou is rapidly advancing, with a focus on innovation in drug development and high-end medical devices, positioning itself as a national leader in the sector [5][11][12] Company Overview - Zhejiang Batai Medical Technology Co., Ltd. operates a modern production facility in the core area of "China Medical Port," producing over 2,000 drug balloons daily, which are crucial for vascular intervention surgeries [6][9] - Batai Medical has developed a breakthrough product, the "Matrix Super PTX™ constrained drug balloon," which is recognized as the second globally and the first in China, enhancing drug delivery precision and reducing vascular damage [8][9] Industry Development - Hangzhou's biopharmaceutical industry has reached a scale of "hundred billion output value and three hundred billion revenue," with 357 industrial enterprises, including 25 listed companies, contributing to high-quality development [5][11] - The city is recognized as a key player in the national biopharmaceutical industry, particularly in new drug research and digital healthcare, while still facing challenges compared to cities like Shanghai and Beijing [11][12] Innovation and Policy Support - Continuous investment in R&D is essential for companies in the biopharmaceutical sector, with Batai Medical emphasizing the importance of innovation and product upgrades to maintain competitiveness [7][10] - The local government has implemented supportive policies, including financial subsidies and measures to accelerate the development of the biopharmaceutical industry, fostering an environment conducive to innovation [8][13][14] Future Outlook - Batai Medical aims to enhance its capabilities by overcoming key technological challenges and expanding its product line, while also seeking to strengthen its market presence both domestically and internationally [10][12] - Hangzhou's biopharmaceutical industry is set to achieve ambitious goals by 2026, including the cultivation of multiple billion-dollar enterprises and a significant increase in listed companies [14]

Core Insights - The conference "2025 Financial Empowerment of the Medical and Health Industry (Guangxi) Innovation Conference" was successfully held in Nanning, focusing on building a closed-loop ecosystem of "technology innovation + capital empowerment + industry landing" to support Guangxi in becoming a healthcare industry hub facing ASEAN [2] - The "2025 China Innovative Drug Industry Investment Blue Book" was jointly released, providing authoritative and practical development trend analysis and investment layout guidance for industry participants, investors, and policymakers [2] Industry Development Background - The demand for innovative drugs is shifting from "curative" to "long-term management" and "precision" due to population aging and chronic diseases [6] - The number of rare diseases is increasing, necessitating the development of effective treatments [6] - AI-driven drug development is shortening research cycles, and innovative biopharmaceutical technologies are flourishing [6] Global Innovative Drug Development Trends - The number of innovative drugs in the oncology field is steadily increasing, with its share rising from 35% in 2020 to 45% in 2024, driven by breakthroughs in targeted therapies and CAR-T cell therapies [8] - From 2015 to 2024, a total of 12,263 innovative drugs are expected to be developed globally, with 9,427 still active by the end of 2024 [10] - China has become the country with the most innovative drugs since 2020, reaching 704 by 2024, surpassing the U.S. [11] China’s Innovative Drug Industry Development - The Chinese innovative drug industry has evolved through four stages: initial stage, combination of imitation and innovation, rise of innovation, and globalization [19] - The policy environment has increasingly focused on supporting innovative drugs, with a systematic policy matrix established to accelerate their transition from laboratory to clinical application [17] Market Size and Financing Trends - The innovative drug market in China is projected to reach CNY 1,620 billion by 2024, with commercial health insurance accounting for only 7.7% of the payment market [25] - The financing landscape has shifted from a focus on quantity to quality, with a notable increase in the proportion of domestic companies' innovative drugs approved in China, rising from under 10% in 2015 to 50% in 2024 [23] Future Opportunities and Challenges - The aging population and the demand for innovative drugs in oncology and chronic diseases are expected to continue growing [69] - The industry faces challenges such as geopolitical tensions, regulatory tightening, and high-risk characteristics of drug development, which typically takes over 10 years and requires substantial investment [71][72]

Core Insights - The global biopharmaceutical innovation landscape is undergoing a significant structural change, with China's innovative drug industry emerging as a key player on the global stage, transitioning from a "fast follower" to a "first mover" [2] - China's share in global clinical trials and licensing transactions has notably increased, with Chinese biotech companies' stock prices outperforming their U.S. counterparts over the past year, indicating a historic investment opportunity [2][3] - The trend of multinational corporations (MNCs) increasingly sourcing early-stage innovation pipelines from China is becoming more pronounced, driven by cost-effectiveness and superior outcomes [3] Group 1 - China's innovative drug companies can advance drug discovery from target identification to IND application 2-3 times faster than international peers, and patient recruitment in clinical development is 2-5 times quicker, with costs per patient being half of those in Europe and the U.S. [5] - The total amount of external licensing transactions for Chinese innovative drugs surpassed $100 billion in the first three quarters of 2025, highlighting the immense potential for value realization in the domestic market [5] - Significant collaborations, such as the $12.5 billion agreement between 3SBio and Pfizer, have sparked renewed interest in the capital market, leading to a 60.27% increase in the Hang Seng Innovation Drug Index in June [3][5] Group 2 - The current surge in business development (BD) activities is driven by MNCs recognizing the continuous improvement in China's innovation, research, and clinical capabilities, prompting large-scale acquisitions [6] - Investment institutions are focusing on the biopharmaceutical sector, where approximately 80% of market value is concentrated, leading to a clear investment path for capital [6][7] - The market is witnessing a shift towards more innovative collaboration models, such as the "Co-Co model" between Innovent Biologics and Takeda, with potential transaction values reaching $11.4 billion [5] Group 3 - The Chinese innovative drug sector is expected to thrive, with projections indicating a prosperous pharmaceutical industry by 2025, supported by favorable policies and recovering valuations [9] - The overall revenue of listed Chinese innovative drug companies reached 48.83 billion yuan in the first three quarters of 2025, marking a 22% year-on-year increase, with the sector achieving its first quarterly profit since its inception [9] - The Hong Kong market is experiencing a threefold increase in trading volume compared to last year, with both domestic and foreign funds actively investing in the Chinese market [9][10] Group 4 - The capital market is transitioning from a focus on narrative-driven investments to a preference for companies with solid fundamentals, emphasizing the importance of clinical data and asset quality [11][12] - The interaction between A-share and Hong Kong markets is tightening, with a trend of high-quality blue-chip assets seeking listings in Hong Kong, reflecting a more rigorous examination of companies' fundamentals [14][15] - Companies with strong fundamentals are more likely to succeed in the capital market, while those lacking solid foundations may struggle to capitalize on market opportunities [16][17]

Core Viewpoint - The global biopharmaceutical innovation landscape, traditionally dominated by multinational corporations (MNCs), is undergoing a significant structural change, with China's innovative drug industry emerging as a key player on the global stage [1][4]. Group 1: Market Dynamics - China's share in global clinical trials and licensing transactions has significantly increased, with Chinese biotech companies' stock prices outperforming their U.S. counterparts over the past year [1]. - The total market capitalization of Chinese listed biotech companies is still less than 15% of their U.S. peers, indicating a historical investment opportunity as international capital views this as a chance for growth [1]. - The collaboration between domestic companies and MNCs is intensifying, with a notable trend of MNCs increasingly sourcing early-stage innovation pipelines from China [2][4]. Group 2: Cost and Efficiency Advantages - Chinese innovative drug companies exhibit a unique dual advantage of speed and cost-effectiveness, advancing drug discovery phases 2-3 times faster than international counterparts and recruiting clinical trial patients at half the cost [6]. - The total amount of licensing transactions for Chinese innovative drugs is expected to exceed $100 billion in the first three quarters of 2025, reflecting the immense potential for value realization in the domestic market [6]. Group 3: Business Development (BD) Trends - The BD activity in the innovative drug market is thriving, with significant transactions such as the $12.5 billion upfront payment from Pfizer to 3SBio marking a record for domestic innovative drugs [4][10]. - The market is witnessing a shift towards more innovative collaboration models, such as the "Co-Co model" between Innovent Biologics and Takeda, which involves joint development and commercialization [6]. Group 4: Investment Sentiment and Market Outlook - The pharmaceutical industry is projected to experience robust growth by 2025, with the Hang Seng Index expected to double, driven by favorable policies and a rebound in industry valuations [10]. - The innovative drug sector has shown a 22% year-on-year revenue growth, with the sector achieving its first quarterly profit of 1.1 billion yuan in Q3 2025 [10]. - The market is characterized by a cautious optimism, with a significant increase in trading volume and participation from both domestic and foreign funds, indicating a healthy and sustainable market environment [10][11]. Group 5: Regulatory and Market Considerations - The interaction between A-share and Hong Kong markets is expected to tighten, with many quality blue-chip assets seeking to transition from A-shares to Hong Kong listings [15]. - The market has returned to a rational state, with investors focusing more on the fundamentals of companies rather than speculative narratives, emphasizing the importance of a clear commercialization path and sustainable profitability for successful listings [15][18].

Core Viewpoint - Dongyangguang Pharmaceutical has made significant strides in the field of innovative drug development, particularly with its core drug HECN30227, which offers hope for clinical cure for hepatitis B patients in China [2][3]. Company Development - Established in 2003, Dongyangguang Pharmaceutical has transformed from a generic drug brand to a comprehensive pharmaceutical company focused on innovative drugs, targeting areas such as infections, chronic diseases, and tumors [2][3]. - The company has developed three self-researched new drugs and has nearly 50 new drugs in the pipeline, actively seeking international expansion for growth [3][4]. Financial Performance - From 2022 to 2024, the total revenue is projected to reach 14.2 billion yuan, with research and development investment amounting to 2.5 billion yuan over the past three years, and profits exceeding 2.1 billion yuan in the last two years [4][5]. Innovation and R&D - The company emphasizes the long-term commitment required for innovative drug development, with the first new drug, phosphoric acid emetine, taking ten years from project initiation to market launch [5]. - Dongyangguang Pharmaceutical has a robust R&D system, including a modern factory with an annual production capacity of 1.8 billion tablets and a national key laboratory for new anti-infection drug research [6]. AI and Digitalization - The company is actively integrating AI into its drug discovery process, having established a partnership with Huawei Cloud and DeepMind Technology to create an "AI + biomedicine" ecosystem [7]. International Expansion - Dongyangguang Pharmaceutical aims to expand internationally, with a sales network covering eight countries, including the US, Germany, and the UK [9][10]. - The company has three clear pathways for international growth: internationalization of mature products, authorized cooperation for innovative drugs, and overseas market entry for self-developed products [10]. Commitment to Quality - Dongyangguang Pharmaceutical is committed to providing high-quality, affordable insulin products for the global diabetes population, aiming to be the first domestic company to obtain approval for its insulin products in the US [10][11].